The biopharmaceutical world is in a constant state of flux.
This flux is driven by scientific breakthroughs, evolving patient needs, and increasingly, the relentless march of technology.
In this dynamic landscape, Neurocrine Biosciences, a company long committed to alleviating suffering through “brave science,” has made a strategic move.
This move signals its intent to harness the digital frontier.
The strategic move is the appointment of Lewis Choi as its Chief Information Officer, effective June 9, 2025.
This isn’t merely a new hire.
It’s a clear declaration of how integral information technology and artificial intelligence are becoming to the very core of drug discovery, development, and delivery.
Choi arrives at Neurocrine with an impressive quarter-century of experience.
This experience is etched into the rapidly evolving domains of IT and AI.
His 13-year tenure at Thermo Fisher Scientific serves as a powerful testament to his capabilities.
Thermo Fisher Scientific is a global giant in scientific instrumentation and services.
Most recently, he held the pivotal role of Vice President of AI Automation & Data.
This title speaks volumes about the strategic importance placed on intelligent systems and data utilization in modern science.
Prior to that, his leadership spanned global digital platforms, engineering, generative AI, and digital solutions.
These roles covered diverse markets, including APAC and emerging economies.
This extensive background suggests a leader adept at building robust technological infrastructure.
It also suggests a leader skilled at leveraging cutting-edge AI to extract insights and automate complex processes.
Such skills are becoming indispensable in the data-rich realm of biopharma.
Matt Abernethy, Neurocrine’s Chief Financial Officer, articulated the company’s vision behind Choi’s appointment with precision.
He highlighted Choi as a “proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change.” [source]
This insight goes beyond mere technical proficiency.
It points to Choi’s ability to integrate technology seamlessly into an organization’s fabric, fostering an environment where innovation thrives.
For a company like Neurocrine, deeply rooted in scientific research and patient care, this cultural aspect is paramount.
It’s about empowering scientists, clinicians, and business teams with tools that amplify their impact, rather than simply imposing new systems.
Indeed, Choi joins Neurocrine at what Abernethy aptly describes as an “exciting time.” [source]
The company is actively engaged in the launch of CRENESSITY, a new therapeutic.
Simultaneously, it is working to expand the reach of INGREZZA, its established treatment for tardive dyskinesia.
Furthermore, Neurocrine’s robust pipeline features multiple compounds in mid- to late-phase clinical development.
This underscores a period of intense activity and potential growth.
In this context, the role of technology transcends mere operational support.
It becomes a critical enabler.
Imagine AI algorithms accelerating drug discovery by sifting through vast datasets of molecular compounds.
These algorithms can identify promising candidates with unprecedented speed.
Picture advanced data analytics optimizing clinical trial design.
These analytics can identify ideal patient populations and monitor outcomes with greater precision.
Envision digital platforms enhancing patient engagement, providing support, and gathering real-world evidence.
This evidence can inform future treatment strategies.
These are not futuristic fantasies but increasingly tangible applications of the very expertise Choi brings to the table.
Choi himself echoed this sentiment of excitement and strategic intent.
“I am excited to join Neurocrine at such a pivotal time for the company,” he stated.
He emphasized his eagerness to “leverage innovative IT and digital solutions to strengthen the business and support the teams who work tirelessly to discover, develop and deliver critical treatments for patients.” [source]
This statement reveals a clear understanding of the dual mandate of a modern CIO in healthcare.
That mandate is to bolster the foundational business operations while simultaneously empowering the scientific and development teams.
It’s a recognition that the true value of technology lies not just in efficiency, but in its capacity to accelerate the core mission of improving patient lives.
Neurocrine Biosciences has always positioned itself as a neuroscience-focused biopharmaceutical company.
Its singular purpose is to relieve suffering.
Its portfolio reflects a deep commitment to addressing under-addressed neurological, neuroendocrine, and neuropsychiatric disorders.
This portfolio spans treatments for conditions like tardive dyskinesia, Huntington’s disease-associated chorea, and classic congenital adrenal hyperplasia.
For three decades, the company has applied its unique insight into the intricate connections between brain and body systems to unravel complex conditions.
Now, with Choi at the helm of its information strategy, this “brave science” is poised to become even braver.
It will be propelled by the enhanced capabilities of artificial intelligence and sophisticated digital ecosystems.
The appointment of a seasoned tech leader like Choi into a top executive role within a biopharma company reflects a broader industry trend.
The lines between technology and life sciences are blurring.
Digital transformation ceases to be an optional add-on and becomes a fundamental requirement for competitive advantage.
Companies that embrace this convergence will be best positioned to innovate faster, reach more patients, and ultimately, deliver on their profound societal missions.
These companies leverage data, AI, and digital platforms to optimize every stage from research to commercialization.
Neurocrine Biosciences, by bringing Lewis Choi on board, is clearly signaling its ambition to be at the forefront of this transformation.
It is ensuring that its brave science is matched by equally brave technology.
The expansion introduces agentic decision flows to bolster investigative capabilities for a national security agency in the EMEA region.
Zoho founder Sridhar Vembu warns that companies must prioritize data sovereignty by building internal AI models to protect sensitive intellectual property.
A comparative analysis of market performance, institutional confidence, and operational scale between a global healthcare giant and a specialized biopharmaceutical developer.
